Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2010

01-05-2010 | Epidemiology

Polymorphisms in the UBC9 and PIAS3 genes of the SUMO-conjugating system and breast cancer risk

Authors: Thomas Dünnebier, Justo Lorenzo Bermejo, Susanne Haas, Hans-Peter Fischer, Christiane B. Pierl, Christina Justenhoven, Hiltrud Brauch, Christian Baisch, Michael Gilbert, Volker Harth, Anne Spickenheuer, Sylvia Rabstein, Beate Pesch, Thomas Brüning, Yon-Dschun Ko, Ute Hamann

Published in: Breast Cancer Research and Treatment | Issue 1/2010

Login to get access

Abstract

SUMOylation consists in the covalent conjugation of small ubiquitin-related modifiers to target proteins. SUMOylation participates in processes that are tightly linked to tumorigenesis, and genetic variability in the SUMO-conjugating system may influence the development of breast cancer. We recently reported that variation in the UBC9 gene encoding the SUMO-conjugating enzyme may affect the grade of breast tumors. Following comprehensive in silico analyses for detection of putative functional polymorphisms in 14 genes of the SUMO system, we selected one coding SNP in PIAS3 and seven tag SNPs in UBC9 for association analyses. Results were based on 1,021 cases, and 1,015 matched controls from the population-based GENICA study. Odds ratios (OR) and 95% confidence intervals (CI) were estimated by conditional logistic regression. To explore the association with polymorphisms closely linked to the genotyped variants, multiple imputation based on HapMap data was applied. The study revealed associations of four UBC9 polymorphisms with risk of grade 1 tumors. Comparison of genotype and haplotype models indicated that the best representation of risk solely relied on rs7187167 under dominant penetrance. Women carrying the rare allele showed an increased risk of grade 1 tumors compared with common homozygotes (OR 1.87, 95% CI 1.18–2.95). This effect appeared to be stronger in women with a family history of breast or ovarian cancer. Imputation of polymorphisms in a 300-kb region around the genotyped polymorphisms identified no variants with stronger associations. Our findings suggest that genetic variation in UBC9 may affect the risk of grade 1 breast tumors.
Appendix
Available only for authorised users
Literature
1.
Geiss-Friedlander R, Melchior F (2007) Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol 8:947–956CrossRefPubMed
2.
Muller S, Hoege C, Pyrowolakis G, Jentsch S (2001) SUMO, ubiquitin’s mysterious cousin. Nat Rev Mol Cell Biol 2:202–210CrossRefPubMed
3.
4.
5.
Seeler JS, Bischof O, Nacerddine K, Dejean A (2007) SUMO, the three Rs and cancer. Curr Top Microbiol Immunol 313:49–71CrossRefPubMed
6.
Gostissa M, Hengstermann A, Fogal V, Sandy P, Schwarz SE, Scheffner M, Del Sal G (1999) Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1. EMBO J 18:6462–6471CrossRefPubMed
7.
Muller S, Berger M, Lehembre F, Seeler JS, Haupt Y, Dejean A (2000) c-Jun and p53 activity is modulated by SUMO-1 modification. J Biol Chem 275:13321–13329CrossRefPubMed
8.
Muller S, Matunis MJ, Dejean A (1998) Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J 17:61–70CrossRefPubMed
9.
Rodriguez MS, Desterro JM, Lain S, Midgley CA, Lane DP, Hay RT (1999) SUMO-1 modification activates the transcriptional response of p53. EMBO J 18:6455–6461CrossRefPubMed
10.
Eladad S, Ye TZ, Hu P, Leversha M, Beresten S, Matunis MJ, Ellis NA (2005) Intra-nuclear trafficking of the BLM helicase to DNA damage-induced foci is regulated by SUMO modification. Hum Mol Genet 14:1351–1365CrossRefPubMed
11.
Kawabe Y, Seki M, Seki T, Wang WS, Imamura O, Furuichi Y, Saitoh H, Enomoto T (2000) Covalent modification of the Werner’s syndrome gene product with the ubiquitin-related protein, SUMO-1. J Biol Chem 275:20963–20966CrossRefPubMed
12.
Bossis G, Malnou CE, Farras R, Andermarcher E, Hipskind R, Rodriguez M, Schmidt D, Muller S, Jariel-Encontre I, Piechaczyk M (2005) Down-regulation of c-Fos/c-Jun AP-1 dimer activity by sumoylation. Mol Cell Biol 25:6964–6979CrossRefPubMed
13.
Xirodimas DP, Chisholm J, Desterro JM, Lane DP, Hay RT (2002) P14ARF promotes accumulation of SUMO-1 conjugated (H)Mdm2. FEBS Lett 528:207–211CrossRefPubMed
14.
Mo YY, Yu Y, Theodosiou E, Rachel Ee PL, Beck WT (2005) A role for Ubc9 in tumorigenesis. Oncogene 24:2677–2683CrossRefPubMed
15.
Cheng J, Bawa T, Lee P, Gong L, Yeh ET (2006) Role of desumoylation in the development of prostate cancer. Neoplasia 8:667–676CrossRefPubMed
16.
Wang L, Banerjee S (2004) Differential PIAS3 expression in human malignancy. Oncol Rep 11:1319–1324PubMed
17.
Moschos SJ, Smith AP, Mandic M, Athanassiou C, Watson-Hurst K, Jukic DM, Edington HD, Kirkwood JM, Becker D (2007) SAGE and antibody array analysis of melanoma-infiltrated lymph nodes: identification of Ubc9 as an important molecule in advanced-stage melanomas. Oncogene 26:4216–4225CrossRefPubMed
18.
Wu F, Zhu S, Ding Y, Beck WT, Mo YY (2009) MicroRNA-mediated regulation of Ubc9 expression in cancer cells. Clin Cancer Res 15:1550–1557CrossRefPubMed
19.
Karamouzis MV, Konstantinopoulos PA, Badra FA, Papavassiliou AG (2008) SUMO and estrogen receptors in breast cancer. Breast Cancer Res Treat 107:195–210CrossRefPubMed
20.
Ali S, Coombes RC (2000) Estrogen receptor alpha in human breast cancer: occurrence and significance. J Mammary Gland Biol Neoplasia 5:271–281CrossRefPubMed
21.
Sentis S, Le Romancer M, Bianchin C, Rostan MC, Corbo L (2005) Sumoylation of the estrogen receptor alpha hinge region regulates its transcriptional activity. Mol Endocrinol 19:2671–2684CrossRefPubMed
22.
Chauchereau A, Amazit L, Quesne M, Guiochon-Mantel A, Milgrom E (2003) Sumoylation of the progesterone receptor and of the steroid receptor coactivator SRC-1. J Biol Chem 278:12335–12343CrossRefPubMed
23.
Kotaja N, Karvonen U, Janne OA, Palvimo JJ (2002) The nuclear receptor interaction domain of GRIP1 is modulated by covalent attachment of SUMO-1. J Biol Chem 277:30283–30288CrossRefPubMed
24.
Wu H, Sun L, Zhang Y, Chen Y, Shi B, Li R, Wang Y, Liang J, Fan D, Wu G et al (2006) Coordinated regulation of AIB1 transcriptional activity by sumoylation and phosphorylation. J Biol Chem 281:21848–21856CrossRefPubMed
25.
Dunnebier T, Bermejo JL, Haas S, Fischer HP, Pierl CB, Justenhoven C, Brauch H, Baisch C, Gilbert M, Harth V et al (2009) Common variants in the UBC9 gene encoding the SUMO-conjugating enzyme are associated with breast tumor grade. Int J Cancer 125:596–602CrossRefPubMed
26.
Pesch B, Ko Y, Brauch H, Hamann U, Harth V, Rabstein S, Pierl C, Fischer HP, Baisch C, Justenhoven C et al (2005) Factors modifying the association between hormone-replacement therapy and breast cancer risk. Eur J Epidemiol 20:699–711CrossRefPubMed
27.
Justenhoven C, Hamann U, Pesch B, Harth V, Rabstein S, Baisch C, Vollmert C, Illig T, Ko YD, Bruning T et al (2004) ERCC2 genotypes and a corresponding haplotype are linked with breast cancer risk in a German population. Cancer Epidemiol Biomarkers Prev 13:2059–2064PubMed
28.
Justenhoven C, Pierl CB, Haas S, Fischer HP, Baisch C, Hamann U, Harth V, Pesch B, Bruning T, Vollmert C et al (2008) The CYP1B1_1358_GG genotype is associated with estrogen receptor-negative breast cancer. Breast Cancer Res Treat 111:171–177CrossRefPubMed
29.
del Val C, Pelz O, Glatting K-H, Barta E, Hotz-Wagenblatt A (2009) PromoterSweep: a tool for identification of transcription factor binding sites. Theor Chem Acc (in press)
30.
Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA, Belmont JW, Boudreau A, Hardenbol P, Leal SM et al (2007) A second generation human haplotype map of over 3.1 million SNPs. Nature 449:851–861CrossRefPubMed
31.
Ramensky V, Bork P, Sunyaev S (2002) Human non-synonymous SNPs: server and survey. Nucleic Acids Res 30:3894–3900CrossRefPubMed
32.
Thomas PD, Campbell MJ, Kejariwal A, Mi H, Karlak B, Daverman R, Diemer K, Muruganujan A, Narechania A (2003) PANTHER: a library of protein families and subfamilies indexed by function. Genome Res 13:2129–2141CrossRefPubMed
33.
Thomas PD, Kejariwal A, Guo N, Mi H, Campbell MJ, Muruganujan A, Lazareva-Ulitsky B (2006) Applications for protein sequence-function evolution data: mRNA/protein expression analysis and coding SNP scoring tools. Nucleic Acids Res 34(Web Server issue):W645–650
34.
Westfall PH, Young SS (1993) Resampling-Based Multiple Testing. Wiley, New York
35.
Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA (2002) Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 70:425–434CrossRefPubMed
36.
Marchini J, Howie B, Myers S, McVean G, Donnelly P (2007) A new multipoint method for genome-wide association studies by imputation of genotypes. Nat Genet 39:906–913CrossRefPubMed
37.
Antoniou AC, Easton DF (2003) Polygenic inheritance of breast cancer: implications for design of association studies. Genet Epidemiol 25:190–202CrossRefPubMed
38.
Daniels RJ, Peden JF, Lloyd C, Horsley SW, Clark K, Tufarelli C, Kearney L, Buckle VJ, Doggett NA, Flint J et al (2001) Sequence, structure and pathology of the fully annotated terminal 2 Mb of the short arm of human chromosome 16. Hum Mol Genet 10:339–352CrossRefPubMed
39.
40.
Shen Q, Uray IP, Li Y, Krisko TI, Strecker TE, Kim HT, Brown PH (2008) The AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors. Oncogene 27:366–377CrossRefPubMed
41.
42.
43.
44.
Yang W, Paschen W (2009) Gene expression and cell growth are modified by silencing SUMO2 and SUMO3 expression. Biochem Biophys Res Commun 382:215–218CrossRefPubMed
Metadata
Title
Polymorphisms in the UBC9 and PIAS3 genes of the SUMO-conjugating system and breast cancer risk
Authors
Thomas Dünnebier
Justo Lorenzo Bermejo
Susanne Haas
Hans-Peter Fischer
Christiane B. Pierl
Christina Justenhoven
Hiltrud Brauch
Christian Baisch
Michael Gilbert
Volker Harth
Anne Spickenheuer
Sylvia Rabstein
Beate Pesch
Thomas Brüning
Yon-Dschun Ko
Ute Hamann
Publication date
01-05-2010
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-009-0530-y

Other articles of this Issue 1/2010

Breast Cancer Research and Treatment 1/2010 Go to the issue

Epidemiology

IGF-I during primiparous pregnancy and maternal risk of breast cancer

Letter to the Editor

Are PALB2 mutations associated with increased risk of male breast cancer?

Preclinical study

E-cadherin mediates the aggregation of breast cancer cells induced by tamoxifen and epidermal growth factor

Preclinical study

Antimitotic chemotherapeutics promote adhesive responses in detached and circulating tumor cells

Epidemiology

Breast cancer risk in women who fulfill high-risk criteria: at what age should surveillance start?

Preclinical study

Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits